treatment
Never Give Up Hope
I am thrilled because I have already written two articles for AAMDS and am now writing a third one at their request. I am so grateful to still be well enough to do this.
The first article, written in 2017, talked about my initial diagnosis in 2010 of MDS del5Q. MDS is separated into 5 categories and typically patients live the longest with this extremely rare type.
MPN Non-Transplant Therapies - From the 2024 Seattle Patient and Family Conference
Dr. Anna Halpern describes treatment options for Myeloproliferative Neoplasms for patients who will not be treated by a bone marrow transplant. This recording is a session from the 2024 Seattle Patient and Family Conference, ready for on-demand viewing.
MPN (Myeloproliferative Neoplasms) and Transplant Therapies - From the 2024 Seattle Patient/Family Conference
Dr. Rachel Salit explains the condition, Myeloproliferative Neoplasms, along with treatment options. Her session focuses on bone marrow transplantation as a treatment for this rare disease.
MDS and Transplant Therapies - From the 2024 Seattle Patient and Family Conference
When is a bone marrow transplant offered as a treatment for MDS? Which patients are most eligible, and what are possible drawbacks? Watch this session, presented by Dr. Naveed Ali, from the 2024 Seattle Patient and Family Conference to find the answers, and much more.
MDS, or Myelodysplastic Syndromes - From the 2024 Seattle Patient and Family Conference
Aplastic Anemia - From the 2024 Seattle Patient and Family Conference
FDA Approval of PiaSky for Pediatric Patients with PNH, Featuring Satheesh Chonat, MD
Dr. Satheesh Chonat explains how pediatric patients with PNH, or Paroxysmal Nocturnal Hemoglobinuria, may be treated with PiaSky in this recording. Listen now or read transcript below.
FDA Approval of PiaSky for Patients with PNH
Dr. Carlos DeCastro reviews how PiaSky can be used to treat patients with PNH, or Paroxysmal Nocturnal Hemoglobinuria. Listen or read the transcript below.



